Your browser doesn't support javascript.
loading
Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study.
Graul, Emily L; Nordon, Clementine; Rhodes, Kirsty; Marshall, Jonathan; Menon, Shruti; Kallis, Constantinos; Ioannides, Anne E; Whittaker, Hannah R; Peters, Nicholas S; Quint, Jennifer K.
Affiliation
  • Graul EL; School of Public Health and.
  • Nordon C; AstraZeneca, Cambridge, United Kingdom; and.
  • Rhodes K; AstraZeneca, Cambridge, United Kingdom; and.
  • Marshall J; AstraZeneca, Cambridge, United Kingdom; and.
  • Menon S; Medical and Scientific Affairs, AstraZeneca, London, United Kingdom.
  • Kallis C; School of Public Health and.
  • Ioannides AE; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Whittaker HR; School of Public Health and.
  • Peters NS; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Quint JK; School of Public Health and.
Am J Respir Crit Care Med ; 209(8): 960-972, 2024 04 15.
Article in En | MEDLINE | ID: mdl-38127850
ABSTRACT
Rationale Cardiovascular events after chronic obstructive pulmonary disease (COPD) exacerbations are recognized. Studies to date have been post hoc analyses of trials, did not differentiate exacerbation severity, included death in the cardiovascular outcome, or had insufficient power to explore individual outcomes temporally.

Objectives:

We explore temporal relationships between moderate and severe exacerbations and incident, nonfatal hospitalized cardiovascular events in a primary care-derived COPD cohort.

Methods:

We included people with COPD in England from 2014 to 2020, from the Clinical Practice Research Datalink Aurum primary care database. The index date was the date of first COPD exacerbation or, for those without exacerbations, date upon eligibility. We determined composite and individual cardiovascular events (acute coronary syndrome, arrhythmia, heart failure, ischemic stroke, and pulmonary hypertension) from linked hospital data. Adjusted Cox regression models were used to estimate average and time-stratified adjusted hazard ratios (aHRs).Measurements and Main

Results:

Among 213,466 patients, 146,448 (68.6%) had any exacerbation; 119,124 (55.8%) had moderate exacerbations, and 27,324 (12.8%) had severe exacerbations. A total of 40,773 cardiovascular events were recorded. There was an immediate period of cardiovascular relative rate after any exacerbation (1-14 d; aHR, 3.19 [95% confidence interval (CI), 2.71-3.76]), followed by progressively declining yet maintained effects, elevated after one year (aHR, 1.84 [95% CI, 1.78-1.91]). Hazard ratios were highest 1-14 days after severe exacerbations (aHR, 14.5 [95% CI, 12.2-17.3]) but highest 14-30 days after moderate exacerbations (aHR, 1.94 [95% CI, 1.63-2.31]). Cardiovascular outcomes with the greatest two-week effects after a severe exacerbation were arrhythmia (aHR, 12.7 [95% CI, 10.3-15.7]) and heart failure (aHR, 8.31 [95% CI, 6.79-10.2]).

Conclusions:

Cardiovascular events after moderate COPD exacerbations occur slightly later than after severe exacerbations; heightened relative rates remain beyond one year irrespective of severity. The period immediately after an exacerbation presents a critical opportunity for clinical intervention and treatment optimization to prevent future cardiovascular events.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Pulmonary Disease, Chronic Obstructive / Heart Failure Limits: Humans Language: En Journal: Am J Respir Crit Care Med Journal subject: TERAPIA INTENSIVA Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Pulmonary Disease, Chronic Obstructive / Heart Failure Limits: Humans Language: En Journal: Am J Respir Crit Care Med Journal subject: TERAPIA INTENSIVA Year: 2024 Type: Article